Buy this Article for $5.95

Have a coupon or promotional code? Enter it here:

When you buy this you'll get access to the ePub version, a downloadable PDF, and the ability to print the full article.


  1. Aschenbrenner, Diane S. MS, APRN, BC


* After its year-long safety review, the FDA has announced that it could not identify a clear relationship between bisphosphonates, drugs taken to increase bone density in postmenopausal women, and the development of serious atrial fibrillation, despite one trial that found a statistically significantly greater incidence of it with zoledronic acid (Reclast).


* Physicians and NPs may continue to prescribe bisphosphonates.